Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FLGT 
Fulgent Genetics Inc (FLGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: FLGT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $25.33
1 Year Target Price $25.33
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.98% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 665.44M USD | Price to earnings Ratio - | 1Y Target Price 25.33 |
Price to earnings Ratio - | 1Y Target Price 25.33 | ||
Volume (30-day avg) 3 | Beta 0.83 | 52 Weeks Range 14.57 - 23.99 | Updated Date 08/15/2025 |
52 Weeks Range 14.57 - 23.99 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-01 | When - | Estimate -0.18 | Actual 0.07 |
Profitability
Profit Margin -16.83% | Operating Margin (TTM) -24.1% |
Management Effectiveness
Return on Assets (TTM) -3.74% | Return on Equity (TTM) -4.65% |
Valuation
Trailing PE - | Forward PE 7.94 | Enterprise Value 379899616 | Price to Sales(TTM) 2.19 |
Enterprise Value 379899616 | Price to Sales(TTM) 2.19 | ||
Enterprise Value to Revenue 1.25 | Enterprise Value to EBITDA -4.34 | Shares Outstanding 30609000 | Shares Floating 18639990 |
Shares Outstanding 30609000 | Shares Floating 18639990 | ||
Percent Insiders 33.21 | Percent Institutions 54.62 |
Upturn AI SWOT
Fulgent Genetics Inc
Company Overview
History and Background
Fulgent Genetics Inc. was founded in 2011. Initially focused on developing a comprehensive genetic testing platform, it rapidly grew through strategic partnerships and technological advancements, particularly in next-generation sequencing (NGS). The company pivoted to high-volume COVID-19 testing during the pandemic, significantly boosting revenue, and is now focusing on returning to its core genetics business.
Core Business Areas
- Core Genetic Testing: Offers a wide range of genetic tests covering various medical conditions, including inherited diseases, cancer diagnostics, and reproductive health. These tests use NGS and other technologies.
- COVID-19 Testing (Historically Significant): During the pandemic, Fulgent provided high-volume COVID-19 testing services. While this segment has decreased, it remains a part of offerings
- Therapeutic Development: Fulgent has expanded into therapeutic development.
Leadership and Structure
Ming Hsieh is the Chairman of the Board and CEO. The company has a standard corporate structure with various departments led by vice presidents and directors.
Top Products and Market Share
Key Offerings
- Expanded Carrier Screening: Screens for hundreds of inherited genetic conditions. Competitors include Myriad Genetics, Natera, and LabCorp. Market share data varies, but Fulgent is a significant player in the expanded carrier screening market.
- Oncology Testing: Provides comprehensive genomic profiling for cancer patients. Competitors include Foundation Medicine (Roche), Guardant Health, and Exact Sciences. Fulgent competes on price and breadth of testing, offering a cost effective solution. Market share data varies.
- COVID-19 Testing: PCR-based test for detecting COVID-19. Competitors include Quest Diagnostics, LabCorp, and numerous smaller labs. Revenue and volumes greatly vary. Fulgent quickly scaled up operations and provided test for various institutions.
Market Dynamics
Industry Overview
The genetic testing industry is growing rapidly, driven by advancements in technology, increasing awareness of genetic diseases, and personalized medicine. It includes diagnostics, screening, and therapeutic development. COVID-19 has accelerated adoption of genetic testing.
Positioning
Fulgent is positioned as a cost-effective provider of comprehensive genetic testing services. It competes on price, turnaround time, and the breadth of its test menu. Focuses on scalability through automation and efficient operations.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions of USD in the next few years. Fulgent is focusing on capturing a larger share of this expanding market by expanding test menu and building direct to patient programs
Upturn SWOT Analysis
Strengths
- Comprehensive test menu
- Competitive pricing
- Scalable technology platform
- Strong relationships with healthcare providers
- Focus on automation
Weaknesses
- Dependence on COVID-19 testing revenue (decreasing)
- Lower brand recognition compared to larger competitors
- Need to expand sales and marketing efforts
- Reliance on reimbursement rates
Opportunities
- Expanding into new geographic markets
- Developing new genetic tests
- Acquiring complementary businesses
- Entering partnerships with pharmaceutical companies
- Direct-to-consumer genetics offerings
Threats
- Increasing competition
- Changes in reimbursement policies
- Regulatory hurdles
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- DGX
- LH
- ILMN
- PACB
- ONT
Competitive Landscape
Fulgent competes by offering comprehensive testing and competitive pricing. They are smaller than established diagnostics firms but offer speed and comprehensive genetic analysis. Competition will be strong as the larger companies have a head start and brand loyalty.
Major Acquisitions
Inform Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 170
- Strategic Rationale: Expanded Fulgent's oncology testing capabilities and reach.
CSI Laboratories
- Year: 2022
- Acquisition Price (USD millions): 33
- Strategic Rationale: Expanded Fulgent's capabilities in hematopathology and oncology testing.
Growth Trajectory and Initiatives
Historical Growth: Rapid growth driven by COVID-19 testing, followed by a decline.
Future Projections: Analysts expect revenue to stabilize and grow as Fulgent focuses on its core genetics business. Projections vary widely.
Recent Initiatives: Acquisitions of Inform Diagnostics and CSI Laboratories and focusing on direct to patient programs and new genetic testing.
Summary
Fulgent Genetics experienced a significant revenue surge during the COVID-19 pandemic, but now focuses on its core genetics business. They face increasing competition in the growing genetic testing market, where innovation is key. Their cost-effective approach and scalability are working to their advantage. Need to look out for changes in reimbursement policies and technological advancements by competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulgent Genetics Inc
Exchange NASDAQ | Headquaters El Monte, CA, United States | ||
IPO Launch date 2016-09-29 | Chairman & CEO Mr. Ming Hsieh | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1313 | Website https://www.fulgentgenetics.com |
Full time employees 1313 | Website https://www.fulgentgenetics.com | ||
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.